The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD)

Abstract

Clinical response to adalimumab therapy is associated with an improvement in linear growth in a proportion of children with CD. Improved growth is more likely in patients entering remission and on immunosuppression but is not solely due to a steroid sparing effect.